Department of Oncology, Aalborg Hospital, Aarhus University, Aalborg, Denmark.
Breast Cancer Res Treat. 2010 May;121(1):91-100. doi: 10.1007/s10549-010-0756-8. Epub 2010 Mar 20.
The purpose of this study was to examine cognitive function in patients with early breast cancer before and after adjuvant chemotherapy or 6 months of tamoxifen. We performed a population-based study in the county of North Jutland, Denmark, including 120 women aged <60 years who received adjuvant chemotherapy with seven cycles of cyclophosphamide, epirubicin and fluoruracil or adjuvant tamoxifen for 6 months for early breast cancer from 2004 to 2006. They were compared with an aged-matched group of 208 women without previous cancer selected randomly from the same population. Data were collected before start of adjuvant treatment and after 6 months by neuropsychological tests and questionnaires to evaluate cognitive function, quality of life and psychological distress. Neuropsychological tests did not reveal any differences in cognitive function between breast cancer patients after chemotherapy and healthy controls. Patients rated their own cognitive functions as improved after 6 months, and patients, who did not receive adjuvant medical treatment, reached the same level as controls within 6 months. Patients receiving chemotherapy or tamoxifen were up to three times more likely than controls to rate themselves as impaired at 6 months. Our results do not support that adjuvant chemotherapy is associated with cognitive side effects in breast cancer patients.
本研究旨在探讨早期乳腺癌患者在接受辅助化疗或他莫昔芬 6 个月治疗前后的认知功能。我们在丹麦北日德兰郡进行了一项基于人群的研究，纳入了 120 名年龄<60 岁的女性，她们在 2004 年至 2006 年间因早期乳腺癌接受了 7 个周期的环磷酰胺、表柔比星和氟尿嘧啶辅助化疗或 6 个月的他莫昔芬辅助治疗。将她们与同一人群中随机选择的 208 名无既往癌症的年龄匹配对照组进行比较。在辅助治疗开始前和 6 个月后，通过神经心理学测试和问卷调查收集数据，以评估认知功能、生活质量和心理困扰。神经心理学测试未显示化疗后乳腺癌患者的认知功能有任何差异。患者在 6 个月后自评认知功能有所改善，而未接受辅助药物治疗的患者在 6 个月内达到与对照组相同的水平。接受化疗或他莫昔芬治疗的患者自评受损的可能性是对照组的 2 至 3 倍。我们的结果不支持辅助化疗与乳腺癌患者的认知副作用有关。
